GSK Predicts Significant Restless Legs Market For Requip
This article was originally published in The Pink Sheet Daily
Executive Summary
The supplemental NDA for the Parkinson's therapy marks the first drug approval for restless legs syndrome. GSK says one in 10 adults have the condition.